Literature DB >> 10870044

Cyclin D and cyclin E expression in normal and adenomatous pituitary.

S Jordan1, K Lidhar, M Korbonits, D G Lowe, A B Grossman.   

Abstract

OBJECTIVES: Cyclins play an important role in the regulation of cell progression through the cell cycle. Over-expression of the cyclins has been shown in many different tumour types. Pituitary adenomas are a common form of endocrine neoplasia in the human, but have been little studied in terms of the expression of the principal cyclins regulating checkpoint exit, cyclin D1 and cyclin E.
METHODS: We therefore investigated the expression of cyclin D1 and cyclin E in a range of benign and metastatic pituitary tumours. We studied a total of 95 pituitaries, including normal pituitary (n=20), Cushing's disease (n=19), somatotroph tumours (n=19), non-functioning adenomas (n=18), prolactinomas (n=7), aggressive tumours (n=9) and pituitary carcinoma (n=3). All tumours and normal tissue were immunostained for cyclin D1 and cyclin E using a standard technique, and were then subjected to blinded analysis by a single observer and the extent of staining quantified on the basis of 500 cell counts per tissue. The distribution of positive staining between different tissues was analysed by non-parametric test procedures.
RESULTS: There was no cytoplasmic staining for cyclin D1 in any tissue. Nuclear staining was generally sparse, but was statistically more frequent in non-functioning and aggressive tumours compared with other tumour types or normal pituitary. Cyclin E was also sparsely expressed, but was specifically increased in corticotroph tumours from patients with Cushing's disease.
CONCLUSIONS: We report cyclin D1 over-expression in aggressive and non-functioning pituitary tumours, and that cyclin E expression is more frequently seen in Cushing's disease. The high level of cyclin E expression in Cushing's disease may relate to the low level of p27 protein expression previously reported in corticotroph tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870044     DOI: 10.1530/eje.0.143r001

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  34 in total

Review 1.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

Review 2.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

4.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

5.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Authors:  Henriett Butz; Kinga Németh; Dóra Czenke; István Likó; Sándor Czirják; Vladimir Zivkovic; Kornélia Baghy; Márta Korbonits; Ilona Kovalszky; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

6.  Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.

Authors:  Ning-Ai Liu; Takako Araki; Daniel Cuevas-Ramos; Jiang Hong; Anat Ben-Shlomo; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2015-05-05       Impact factor: 5.958

7.  p21, an important mediator of quiescence during pituitary tumor formation, is dispensable for normal pituitary development during embryogenesis.

Authors:  Pamela Monahan; Ashley D Himes; Agata Parfieniuk; Lori T Raetzman
Journal:  Mech Dev       Date:  2011-12-01       Impact factor: 1.882

Review 8.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

9.  E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.

Authors:  Cuiqi Zhou; Kolja Wawrowsky; Serguei Bannykh; Shiri Gutman; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2009-10-16

10.  Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry.

Authors:  Yingchao Liu; Jinsong Wu; Guoquan Yan; Ruiping Hou; Dongxiao Zhuang; Luping Chen; Qi Pang; Jianhong Zhu
Journal:  Proteome Sci       Date:  2010-01-29       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.